Drug Price Trends for NDC 52536-0006

Average Pharmacy Cost for 52536-0006

Drug Name	NDC	Price/Unit ($)	Unit	Date
ISOSORBIDE-HYDRALAZINE 20-37.5 MG TABLET	52536-0006-09	0.77793	EACH	2026-03-18
ISOSORBIDE-HYDRALAZINE 20-37.5 MG TABLET	52536-0006-09	0.79612	EACH	2026-02-18
ISOSORBIDE-HYDRALAZINE 20-37.5 MG TABLET	52536-0006-09	0.76695	EACH	2026-01-21
ISOSORBIDE-HYDRALAZINE 20-37.5 MG TABLET	52536-0006-09	0.72987	EACH	2025-12-17

Best Wholesale Price for NDC 52536-0006

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 52536-0006

Last updated: March 13, 2026

What Is the Drug?

NDC 52536-0006 refers to Vumerity (diroximel fumarate), manufactured by Alkermes. It is an oral prescription medication approved by the FDA in October 2019 for the treatment of relapsing forms of multiple sclerosis (MS). It acts as an oral immunomodulator, similar to Tecfidera (dimethyl fumarate).

Market Size and Growth Factors

Current Market Representation

• Global MS market valuation (2022): Approximately $29 billion, with high growth projected due to increasing diagnosis rates.
• U.S. MS drug market (2022): Estimated at $10-12 billion.
• Market penetration: Vumerity's share remains modest; Tecfidera retains about 60-70% of the fumarate class share, with Vumerity holding approximately 10-15%.
• Patient population: U.S. estimated at 1 million diagnosed MS patients; global estimated at 2.8 million (per MS International Federation, 2022).

Competitive Landscape

• Key competitors: Tecfidera (MSD/Merck), Mavenclad (Eli Lilly), Aubagio (Sanofi), and Gilenya (Novartis).
• Differentiators: Vumerity offers a lower gastrointestinal side-effect profile, aiming for better adherence.

Key Market Drivers

• Increasing MS diagnoses.
• Growing preference for oral therapies.
• Favorable reimbursement policies for newer agents.

Challenges

• Competition from established therapies.
• Patent expirations potentially influencing pricing.
• Availability of biosimilars or generics in future markets.

Price Trends and Cost Dynamics

Current Pricing (U.S., 2023)

Parameter	Details
Wholesale Acquisition Cost (WAC) per month	Approx. $8,600 (for 240 mg twice daily)
Average Retail Price (ARP)	Approximately $8,800-$9,200
Patient Out-of-Pocket	$0-$60 (insurers/discount programs)

Price Comparisons with Tecfidera

Drug	WAC/month	Key Differentiator
Vumerity	~$8,600	Lower GI side effects than Tecfidera
Tecfidera	~$8,300	Longer market presence, higher share

Cost Structures and Reimbursement

• Formularies favor established products; newer entrants like Vumerity negotiate discounts.
• Average rebates: 15-20%, reducing net cost to payers.

Market Projections

Short-term Outlook (Next 2 Years, 2023-2024)

• Market share gain: Limited; Vumerity expected to capture an additional 2-3% of the fumarate market.
• Revenue estimate: From approximately $200 million in 2022, projected to reach $350-$400 million by end of 2024, driven by increased adoption.

Mid-term Outlook (2025-2027)

• Market penetration growth: Likely to plateau unless new formulations or indications are approved.
• Price adjustments: Slight reductions (~5%) probable due to competitive pressures and payer negotiations.
• Revenue forecast: Approximates $400 million to $500 million annually by 2027.

Long-term Outlook (Beyond 2027)

• Market saturation: Likely, with potential for biosimilars or generics reducing prices.
• Brand loyalty: Will influence pricing strategies; aggressive discounts may be necessary for sustained market share.

Pricing Strategies and Future Trends

• Manufacturers may implement tiered pricing, discounts, or patient assistance programs.
• Payer pressure could lead to price erosion of 10-15% over five years.
• Emerging biosimilars or generics after patent expiry could halve the drug's price in mature markets.

Key Considerations for Stakeholders

• Patent expiry looming around 2035.
• Innovative delivery systems or new indications could influence long-term pricing.
• Market entry of next-generation oral MS therapies may constrain Vumerity's pricing power.

Key Takeaways

• Vumerity holds a modest market share in a competitive, billion-dollar MS therapy landscape.
• Pricing remains aligned with established oral MS therapies at approximately $8,600 per month.
• Revenue projections indicate gradual growth, reaching up to $500 million annually by 2027 if market penetration increases.
• Competitive pressures and potential generics will influence future prices, likely leading to reductions.
• Adoption will hinge on differentiation factors such as side-effect profile, formulary access, and patient adherence.

FAQs

1. What is the primary differentiator of Vumerity compared to Tecfidera?
   It has a better gastrointestinal tolerance profile, which can improve patient adherence.

2. How does patent expiry influence future pricing?
   Patent expiry around 2035 could lead to generic competition, significantly reducing prices.

3. What is the expected market share of Vumerity in the next five years?
   It could increase from 10-15% to approximately 20-25% as prescribers favor its tolerability.

4. Are there biosimilars or generics expected soon?
   Patent protections delay generics until around 2035; short-to-mid term, biosimilars are unlikely.

5. How might reimbursement policies affect pricing?
   Favorable formulary placements and rebates can sustain sales, but payer negotiations can place downward pressure on prices.

---

References:

1. MS International Federation. (2022). Global MS Data & Statistics.
2. IQVIA. (2022). U.S. MS Market Analysis.
3. FDA. (2019). Approval of Vumerity for MS.
4. Drug Price Data. (2023). Average Wholesale Prices for MS therapies.